Florian Javelle, Wilhelm Bloch, and Philipp Zimmer are with the Clinical Exercise-Neuro-Immunology Group, Department for Molecular and Cellular Sports Medicine, Institute for Cardiovascular Research and Sports Medicine, German Sport University, Cologne, Germany. Amit Lampit is with the Department of Psychiatry, The University of Melbourne, Melbourne, Australia. Amit Lampit is with the Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany. Peter Häussermann is with the University Hospital of Cologne, Cologne, Germany. Sheri Johnson is with the Cal Mania Team, Department of Psychology, University of California Berkeley, Berkley, California, USA. Philipp Zimmer is with the Division of Physical Activity, Prevention and Cancer, German Cancer Research Center, Heidelberg, Germany.
Nutr Rev. 2020 Jan 1;78(1):77-88. doi: 10.1093/nutrit/nuz039.
Serotonergic dysfunction, including reduced central serotonin levels, is associated with different psychiatric syndromes, including depression. As a serotonin precursor, 5-hydroxytryptophan has long been used as a nonpharmacological treatment for depression.
A systematic review and meta-analysis was conducted to determine the antidepressant effects of 5-hydroxytryptophan in depressed patients.
MEDLINE (via PubMed) and Google Scholar were searched from inception to May 2018.
Thirteen investigations were included in the systematic review (using PRISMA guidelines), and 7 in the full meta-analysis (pre-registered on PROSPERO: CRD42018104415).
Analyses revealed a depression remission rate of 0.65 (95% confidence interval [CI], 0.55-0.78; remission rate [k] = 13), and this was confirmed by the questionnaire results, which revealed a large Hedges' g (1.11; 95%CI, 0.53-1.69). Methodological variability (in treatment duration, type of depression studied, experimental design, 5-hydroxytryptophan dosage) contributes to heterogeneity in the results (I2 = 76%, τ2 = 0.379). In addition, the OHAT (Office of Health Assessment and Translation risk of bias rating) tool suggested that, on the whole, current studies are relatively weak (few include placebo groups).
Further trials should overcome these limitations by using placebo-controlled studies that include patients with well-defined depression diagnoses, along with strong characterization of psychological and physiological patient characteristics.
血清素能功能障碍，包括中枢血清素水平降低，与包括抑郁症在内的不同精神综合征有关。作为血清素的前体，5-羟色氨酸长期以来一直被用作抑郁症的非药物治疗方法。
系统评价和荟萃分析旨在确定 5-羟色氨酸对抑郁症患者的抗抑郁作用。
从创建到 2018 年 5 月，通过 MEDLINE（通过 PubMed）和 Google Scholar 进行了搜索。
系统评价（使用 PRISMA 指南）包括 13 项研究，全面荟萃分析（在 PROSPERO 上预先注册：CRD42018104415）包括 7 项研究。
分析显示，抑郁症缓解率为 0.65（95%置信区间[CI]，0.55-0.78；缓解率[k] = 13），这通过问卷结果得到证实，结果显示 Hedges' g 较大（1.11；95%CI，0.53-1.69）。方法学变异性（治疗持续时间、研究的抑郁症类型、实验设计、5-羟色氨酸剂量）导致结果的异质性（I2 = 76%，τ2 = 0.379）。此外，OHAT（卫生评估和翻译风险偏倚评估工具）工具表明，总的来说，当前的研究相对较弱（很少包括安慰剂组）。
进一步的试验应通过使用包括具有明确抑郁症诊断的患者的安慰剂对照研究来克服这些限制，并对心理和生理患者特征进行强有力的特征描述。
